文献速递自身炎症与 IgG4 相关病其他结缔组织病

AMETHYST研究:斯蒂尔病合并糖皮质激素难治性巨噬细胞活化综合征的治疗模式与结局

AMETHYST: A Retrospective Cohort Study of Treatment Patterns and Outcomes in Patients With Glucocorticoid-Refractory Macrophage Activation Syndrome Complicating Still's Disease.
PubMed 文献 · Arthritis Rheumatol · 2026-09-07

AMETHYST为回顾性队列研究,纳入欧洲、加拿大和美国8个中心的64例斯蒂尔病合并糖皮质激素难治性MAS患者,其中86%为全身型幼年特发性关节炎。研究描述了真实世界治疗模式与结局:完全MAS实验室缓解率仅10.9%,部分缓解64.1%,MAS复发31.3%,病死率10.9%,提示需要更安全有效的治疗。

要点

  • 糖皮质激素难治性MAS完全实验室缓解率低(10.9%),部分缓解为64.1%。
  • MAS复发见于31.3%的患者,病死率为10.9%,估计一年生存概率为93.75%。
  • 多数患者接受阿那白滞素和/或环孢素联合糖皮质激素治疗。

核心结论

  • 糖皮质激素难治性MAS的实验室缓解率低,且大剂量糖皮质激素联合其他治疗存在毒性,突出需要更安全、更有效的治疗。

研究设计与样本

  • 回顾性队列研究,从欧洲、加拿大和美国8个中心的病历中提取2012年1月1日至2023年3月31日的医疗数据,纳入64例符合标准的糖皮质激素难治性MAS患者。
  • 纳入的MAS指示发作发生于2012年1月1日至2022年9月30日,并符合入选标准。

主要发现

  • 64例患者中55例(86%)为sJIA,9例(14%)为AOSD;53/64(82.8%)在指示发作时为儿童,中位年龄7.0岁。
  • MAS特征包括皮疹(60.4%)、发热(52.8%)和肝脏受累(49.1%)。
  • 所有患者均接受糖皮质激素治疗,多数还接受阿那白滞素(48/64[75%])和/或环孢素(33/64[51.6%])。
  • 7/64(10.9%)达到7项预设实验室参数正常化(完全MAS实验室缓解),41/64(64.1%)至少3项正常化(部分缓解)。
  • 50/64(78.1%)患者糖皮质激素减量,中位时间39.9天;研究者评估完全和部分临床应答分别为24/64(37.5%)和26/64(40.6%)。

关键数值与推荐

  • 完全MAS实验室缓解定义为7项预设实验室参数正常化,发生于7/64(10.9%);部分缓解定义为至少3项正常化,发生于41/64(64.1%)。
  • 研究者对指示MAS发作的临床体征/症状评估:完全应答24/64(37.5%),部分应答26/64(40.6%)。
  • MAS复发20/64(31.3%);死亡7/64(10.9%),估计一年生存概率为93.75%。

临床怎么用

  • 对于斯蒂尔病合并糖皮质激素难治性MAS,应认识到现有方案下完全实验室缓解率低、复发和死亡风险仍存在,需密切监测并探索更安全有效的治疗。

局限性

  • 原文未报告局限性相关内容。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Information is limited on the natural history and current treatment patterns in macrophage activation syndrome (MAS), a life-threatening hyperinflammatory syndrome complicating Still's disease (systemic juvenile idiopathic arthritis [sJIA] and adult-onset Still's disease [AOSD]). AMETHYST aimed to describe real-world treatment patterns and outcomes in glucocorticoid (GC)-refractory MAS complicating Still's disease. METHODS: In this retrospective cohort study, medical data from January 1, 2012, to March 31, 2023, were abstracted from charts of all eligible patients across eight sites in Europe, Canada, and the United States for index MAS episodes (occurring between January 1, 2012, and September 30, 2022, and meeting eligibility criteria). RESULTS: Overall, 55 of 64 included patients (86%) had sJIA and 9 of 64 (14%) had AOSD. Most patients (53/64 [82.8%]) were children at index (median age: 7.0 years). MAS was characterized by rash (60.4%), fever (52.8%), and hepatic involvement (49.1%). All patients received GCs; most were also treated with anakinra (48/64 [75%]) and/or ciclosporin (33/64 [51.6%]). Normalization of seven (complete MAS laboratory remission) or at least three (partial remission) prespecified laboratory parameters occurred in 7 of 64 (10.9%) and 41 of 64 patients (64.1%), respectively. GCs were tapered in 50 of 64 patients (78.1%) (median: 39.9 days). Per investigator assessment of clinical signs/symptoms for the index MAS episode, 24 of 64 (37.5%) and 26 of 64 patients (40.6%) had a complete and partial response, respectively. MAS recurred in 20 of 64 patients (31.3%). Seven of 64 patients (10.9%) died, and the estimated one-year survival probability was 93.75%. CONCLUSIONS: Low MAS laboratory remission rates and toxicities of high-dose GCs combined with other treatments highlight the need for safer, more effective therapies.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Grom A, Antón J, Behrens EM, et al. AMETHYST: A Retrospective Cohort Study of Treatment Patterns and Outcomes in Patients With Glucocorticoid-Refractory Macrophage Activation Syndrome Complicating Still's Disease. Arthritis Rheumatol. 2026. PMID: 42703797. doi:10.1002/art.70326

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。